Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Published:2019-08-01 Issue:8 Volume:5 Page:1132
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Vinayak Shaveta¹²,Tolaney Sara M.³,Schwartzberg Lee⁴,Mita Monica⁵,McCann Georgia⁶,Tan Antoinette R.⁷,Wahner-Hendrickson Andrea E.⁸,Forero Andres⁹,Anders Carey¹⁰¹¹,Wulf Gerburg M.¹²,Dillon Patrick¹³,Lynce Filipa¹⁴,Zarwan Corrine¹⁵,Erban John K.¹⁶,Zhou Yinghui¹⁷,Buerstatte Nathan¹⁷,Graham Julie R.¹⁷,Arora Sujata¹⁷,Dezube Bruce J.¹⁷,Telli Melinda L.¹⁸

Affiliation:

1. Case Comprehensive Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, Ohio

2. currently affiliated with Fred Hutchinson Cancer Research Center, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle

3. Department of Medical Oncology, Center of Breast Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

4. Division of Hematology/Oncology, The West Clinic, Memphis, Tennessee

5. Division of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, California

6. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio

7. Levine Cancer Institute, Atrium Health, Charlotte, North Carolina

8. Department of Medical Oncology, Mayo Clinic Rochester, Rochester, Minnesota

9. Department of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama

10. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill

11. Department of Medicine, University of North Carolina at Chapel Hill

12. Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

13. Division of Hematology/Oncology, University of Virginia, Charlottesville

14. Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC

15. Department of Hematology and Oncology, Lahey Hospital and Medical Center, Burlington, Massachusetts

16. Department of Medicine–Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts

17. TESARO: A GSK Company, Waltham, Massachusetts

18. Department of Medical Oncology, Stanford University School of Medicine, Stanford, California

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/article-pdf/5/8/1132/17773642/jamaoncology_vinayak_2019_oi_190028.pdf

Reference42 articles.

1. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.;Malorni;Breast Cancer Res Treat,2012

2. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.;Gradishar;Eur J Cancer,2013

3. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.;Kim;Lancet Oncol,2017

4. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERIDIAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.;Miles;Eur J Cancer,2017

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.;Miller;N Engl J Med,2007

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer;Immunotherapy;2024-03

2. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors;ESMO Open;2024-02

3. CYB561 promotes HER2+ breast cancer proliferation by inhibiting H2AFY degradation;Cell Death Discovery;2024-01-20

4. Olaparib maintenance has favourable safety profile in TNBC;Medicom Conference Report SABCS 2023;2024-01-11

5. ER-positive and BRCA2-mutated breast cancer: a literature review;European Journal of Medical Research;2024-01-06